PDE4A and Alzheimer disease: Crisaborole 2% ointment, the first topical PDE4 inhibitor, was licensed by the FDA in December 2016 for the treatment of mild-to-moderate AD in children 2 years and older and in March 2020 for infants 3 months of age and older.